Trial · NCT07896655

Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion

NCT07896655, Not applicable, Not yet recruiting, Guangdong Second Provincial General Hospital

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion. Trials, record NCT07896655. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07896655

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
NCT number: NCT07896655
Status: Not yet recruiting
Phases: Not applicable
Enrollment: 818 participants, estimated
Lead sponsor: Guangdong Second Provincial General Hospital
Conditions: Acute Ischemic Stroke, Basilar Artery Occlusion
Interventions: Mechanical thrombectomy, Normothermic saline infusion, 4°C saline infusion
First posted: 2026-10-27
Last updated: 2026-11-06

Source ClinicalTrials.gov

Registered outcomes21

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Distribution of Modified Rankin Scale Scores at 90 Days	90 (±7) days after randomization	The distribution of modified Rankin Scale (mRS) scores at 90 (±7) days after randomization will be assessed across all seven categories (0-6) using a shift analysis. Scores range from 0 (no symptoms) to 6 (death); lower scores indicate less disability.
Secondary	mortality at 90 (±7) days	90 (±7) days after randomization	All-cause mortality at 90 (±7) days after randomization.
Secondary	Independent ambulation	90 (±7) days after randomization	The proportion of participants with a modified Rankin Scale (mRS) score of 0-3 at 90 (±7) days after randomization will be assessed. The mRS ranges from 0 (no symptoms) to 6 (death); lower scores indicate less disability.
Secondary	Functional independence	90 (±7) days after randomization	The proportion of participants with a modified Rankin Scale (mRS) score of 0-2 at 90 (±7) days after randomization will be assessed. The mRS ranges from 0 (no symptoms) to 6 (death); lower scores indicate less disability.
Secondary	Excellent outcome	90 (±7) days after randomization	The proportion of participants with a modified Rankin Scale (mRS) score of 0-1 at 90 (±7) days after randomization will be assessed. The mRS ranges from 0 (no symptoms) to 6 (death); lower scores indicate less disability.
Secondary	Quality of life score	90 (±7) days after randomization	Health-related quality of life at 90 (±7) days after randomization will be assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Index scores calculated using the Chinese value set range from -0.391 (the worst health state) to 1 (full health); higher scores indicate better health-related quality of life.
Secondary	Cerebral infarction volume	Between 72 hours and 7 days after the procedure	Cerebral infarction volume measured on CT or diffusion-weighted MRI obtained between 72 hours and 7 days after the procedure (MRI preferred).
Secondary	Vascular Re-occlusion Rate	Between 24 hours and 7 days after the procedure	Proportion of participants with re-occlusion of the originally occluded artery or a distal vessel, assessed by CTA or MRA between 24 hours and 7 days after the procedure.
Other	Symptomatic Intracranial Hemorrhage Within 72 Hours	Within 72 hours after the procedure	The proportion of participants who develop symptomatic intracranial hemorrhage within 72 hours after the procedure will be assessed according to the Heidelberg Bleeding Classification. Symptomatic intracranial hemorrhage is defined as a new hemorrhage identified on brain imaging associated with neurological deterioration, indicated by an increase of ≥4 points in the total National Institutes of Health Stroke Scale (NIHSS) score, an increase of ≥2 points in a single NIHSS item, or deterioration requiring a major medical or surgical intervention, such as intubation, decompressive hemicraniectomy, or external ventricular drainage, with no alternative explanation for the deterioration. Changes in NIHSS scores are measured relative to the assessment immediately before deterioration. Total NIHSS scores range from 0 to 42, with higher scores indicating greater neurological impairment. This outcome is recorded as present or absent; the Heidelberg Bleeding Classification does not yield a numer
Other	Any Intracranial Hemorrhage	Through day 7 (±1 day) after the procedure or discharge, whichever occurs first	The proportion of participants with any intracranial hemorrhage detected on protocol-specified computed tomography (CT) or magnetic resonance imaging (MRI) will be assessed through day 7 (±1 day) after the procedure or discharge, whichever occurs first. Both symptomatic and asymptomatic hemorrhages will be included. Hemorrhages will be categorized according to the Heidelberg Bleeding Classification, which describes the anatomical location and pattern of bleeding and does not yield a numerical total score. This outcome is recorded as present or absent; minimum and maximum scale scores are not applicable. A higher proportion indicates a worse safety outcome.

1 to 10 of 21Source ClinicalTrials.gov

See all 21 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07896655

GET https://conductscience.org/api/trials/v1/NCT07896655/registered?page=2

API reference For AI assistants